ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST in New York City. During the event, we plan to provide analyses from completed clinical trials, including the full 695 patient dataset from the EF-14 trial in newly diagnosed glioblastoma, data from the PANOVA phase 2 pilot trial in advanced pancreatic cancer and data from the INNOVATE phase 2 pilot trial in recurrent ovarian cancer. In addition, the company will provide an update of recent preclinical findings related to Tumor Treating Fields (TTFields) and a review of its ongoing clinical pipeline.
“I am very pleased with the progress we made in our clinical development programs during the second quarter of 2016,” said Asaf Danziger, Novocure’s Chief Executive Officer. “We enter the back half of the year with a substantial liquidity position and strong preclinical data supporting broad applicability of TTFields to multiple solid tumor indications. With these factors in place, we are excited to share clinical developments that will position us to expand TTFields beyond our current glioblastoma indication. We believe that glioblastoma is only the beginning for TTFields and Novocure, and we are dedicated to developing this technology for patients who have such a vital need for improved treatment options.”
Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, will moderate the event. A live webcast will be accessible from novocure.com. Portions of the event will be available for replay on the company’s website for at least 14 days.
Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investors
Ashley Cordova, 212-767-7558